Bioventus
BVS
53 hedge funds and large institutions have $364M invested in Bioventus in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 12 closing their positions.
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
18% more funds holding
Funds holding: 45 → 53 (+8)
7% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.82% less ownership
Funds ownership: 53.3% → 50.48% (-2.8%)
28% less capital inflows, than outflows
Capital inflows: $42.5M | Capital outflows: $59.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuance Investments
Kansas City,
Missouri
|
+$11.2M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$6.44M |
| 3 |
JP Morgan Chase
New York
|
+$5.85M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.89M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$2.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avidity Partners Management
Dallas,
Texas
|
-$19.2M |
| 2 |
Millennium Management
New York
|
-$11.4M |
| 3 |
Pura Vida Investments
New York
|
-$5.36M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$4.27M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$3.82M |
BVS Hedge Fund Activity: Q2 2021 in Review
53 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q2 2021, worth a combined $364M — up 9.1% from $334M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new BVS positions and 12 closed out — a net gain of 8 holders — while 15 added to existing stakes and 14 trimmed.
The largest buyer was Nuance Investments, opening a new position worth an estimated $11.2M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $19.2M sold.
- 53 institutional investors held Bioventus (BVS) as of Q2 2021, up from 45 in Q1 2021.
- Funds reported $364M of Bioventus stock for Q2 2021, up 9.1% quarter-over-quarter.
- 20 funds opened new Bioventus positions in Q2 2021 and 12 closed out, a net change of +8 holders.
- The largest Bioventus buyer in Q2 2021 was Nuance Investments, an estimated $11.2M added.
- The largest Bioventus seller in Q2 2021 was Avidity Partners Management, an estimated $19.2M sold.
Based on aggregated 13F filings for Q2 2021.